Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Merck

More drug companies sign on to Trump’s health exchange that promises to lower prescription prices

Administration officials say the ‘Trump Rx’ website should be up and running next month

The Independent UK

Boss of drugs giant GSK declares US best place to invest

Dame Emma Walmsley said the US was still leading the way for new drugs and vaccines.

Evening Standard

What will be the cost of Keir Starmer’s new medicines deal with Donald Trump? British lives

More than £3bn that could have been used for UK patients will go to big pharma for its branded products, says Guardian columnist Aditya Chakrabortty

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Dividend Stocks for 2026: Where to Invest as the Market Cools

These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.

MarketBeat

FDA opens safety review of injectable RSV drugs approved for babies and toddlers

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV virus

The Independent UK

These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now

Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.

Barchart

2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The Dow Jones Looks Ready for Death, But These 3 Blue-Chip Stocks Have More Life (and Gains) Ahead

These three stocks have healthy charts in an index that’s looking sick.

Barchart

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

MarketBeat

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.

MarketBeat

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.

Benzinga

‘Patients will suffer’: tales from the frontline of the UK pharma crisis

The pricing standoff between government and industry has stalled research and put thousands of jobs at risk

The Guardian - UK

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Benzinga

Invo Fertility Stock Is Plunging After White House Announcement

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients

Merck Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s (OTC:RHHBY) Avastin (bevacizumab).

Benzinga

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Barchart

Merck & Co. Earnings Preview: What to Expect

Healthcare giant Merck & Co. is gearing up to unveil its third-quarter results by the end of October, and analysts expect a massive surge in earnings.

MarketBeat

2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk

Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Over 150 unvaccinated students stuck in three-week quarantine for measles exposure

Two South Carolina schools forced to tell 153 kids to stay home for 21 days to allow for virus’s transmission period to expire in order to protect their peers and teachers

MarketBeat

5 Healthcare Plays Powering the Sector’s Big Comeback

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

Benzinga

Merck, Doctors Reject Proposal To Break Up Combined MMR Vaccine

A top U.S. health official's call to split the measles-mumps-rubella (MMR) vaccine into separate shots sparked strong pushback from Merck Co., Inc. (NYSE:MRK) and medical experts, who said such a move lacks scientific justification and could undermine immunization efforts.

Benzinga

Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients

Merck Co. Inc. (NYSE:MRK) announced results Tuesday from its Phase 3 HYPERION trial evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression.

The Conversation

The UK must invest in medicines – but not at any price

The UK’s science minister, Sir Patrick Vallance, has sounded the alarm over the country’s declining investment in medicines. He warned that the NHS risks losing out on important treatments and the country could lose its place at the cutting edge of medical research if spending does not recover. It comes…

The Independent UK

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

The Independent UK

Mounjaro manufacturer blasts UK as ‘worst country in Europe’ for drug prices

The boss of Eli Lilly, Dave Ricks, warns that Britain will miss out on new drugs as a result of pricing issues

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.